Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2024 08:00 ET | Source: Upstream Bio, Inc.

Upstream Bio Announces Oral Presentation of New Data from a Phase 1b Multiple Ascending Dose Trial of Verekitug (UPB-101) in Adults with Asthma at the European Respiratory Society Congress

Upstream gives oral presentation of clinical data for verekitug in patients with severe asthma at European Respiratory Society congress
August 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the...
February 17, 2023 07:00 ET | Source: FibroGen, Inc.

FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results

SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
August 09, 2021 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
March 20, 2019 09:17 ET | Source: Shepherd Smith Edwards & Kantas LLP

Shepherd, Smith, Edwards & Kantas Assisting Puerto Rico ERS Bondholders Collect $3 Billion in Previously Invalidated Collateral

HOUSTON, March 20, 2019 (GLOBE NEWSWIRE) -- Lawyers with the firm Shepherd, Smith, Edwards & Kantas, LLP (SSEK Law Firm) are assisting Employee Retirement System (ERS) bondholders gain access to...
September 05, 2017 16:05 ET | Source: FibroGen, Inc.

FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017

SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...